Adjuvant radiotherapy

辅助放疗
  • 文章类型: Journal Article
    治疗腮腺复发性多形性腺瘤(RPA)的标准手术方法是保留面神经的腮腺切除术(FN)。RPA的治疗仍然具有挑战性,因为在复发方面存在争议,翻修手术的程度,术后放疗,以及保护FN的困难。我们在2017年至2022年期间对腮腺良性肿瘤患者的医疗记录进行了回顾性审查,以确定接受RPA手术的患者。人口统计信息,手术干预细节,术前术后面神经功能,组织病理学分析,并收集复发率。比较了单个复发性肿瘤患者与多个复发性肿瘤患者的这些变量。21名患者符合标准,包括13例首次复发,7第二次复发,1第三次复发。在多次RPA手术后,FN的长期结局显著恶化(P=0.005).没有观察到肿瘤复发的危险因素。最初的翻修手术与随后的翻修手术之间的间隔大大缩短。我们的研究表明,在随后的外科手术中,永久性面瘫的风险更大。早期发现复发有助于早期再次手术。
    The standard surgical procedure for treating the parotid gland\'s recurrent pleomorphic adenoma (RPA) is parotidectomy with facial nerve preservation (FN). Treatment of RPA remains challenging since controversies occur regarding recurrence, degree of revision surgery, postoperative radiation, and difficulty in conserving the FN. A retrospective review of patient\'s medical records treated for benign parotid neoplasms was conducted between 2017 and 2022 to identify individuals who underwent surgery for RPA. Demographic information, surgical intervention details, pre-and postoperative facial nerve function, histopathological analysis, and recurrence rates were collected. These variables were compared in patients with single recurrent tumors versus patients with multiple recurrent tumors. Twenty-one patients met the criteria, including 13 with a first recurrence, 7 with a second recurrence, and 1 with a third recurrence. Following surgery for multiple RPA, long-term FN outcomes were significantly worse (P = 0.005). There were no observable risk factors for tumor recurrence. The interval between the initial revision surgery and subsequent ones was drastically shortened. Our study suggests that the risk of permanent facial paralysis is greater with subsequent surgical procedures. Early detection of recurrence can aid in early re-operation.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    本研究旨在探讨临床和病理特征,治疗策略,子宫内未接触己烯雌酚的宫颈透明细胞癌(CCCC)的预后。
    本回顾性研究纳入2011年1月至2023年6月在四川大学华西第二医院确诊的CCCC患者。收集患者的临床特点、治疗及随访资料。进行Kaplan-Meier方法和Cox回归分析以确定预测无进展生存期(PFS)和总生存期(OS)的相关变量。
    在49名患者中,国际妇产科联合会(FIGO)(2018)分期分布为37(75.5%)一期,6(12.2%)第二阶段,和6(12.2%)第三阶段。中位随访时间为24.1个月。6例(12.2%)患者复发,5例(10.2%)患者死亡。5年PFS率为86.8%,5年OS率为88.2%。在两名成功完成保留生育力治疗的患者和七名接受手术以保留卵巢的患者中未发现复发或死亡。两个病人怀孕了,生了两个婴儿。单因素分析表明,FIGO阶段,盆腔淋巴结(PLN)转移,淋巴血管间隙侵入,基质浸润深度与PFS和OS显著相关(P<0.05)。然而,在多变量分析中没有发现显著的预后因素.
    保留卵巢的治疗和保留生育的手术在早期CCCC中是安全可行的。对于没有任何病理危险因素的早期CCCC,除辅助治疗外的其他监测可能是更好的选择。在未来的研究中应该寻求更多的靶向治疗和免疫疗法。
    UNASSIGNED: This study aimed to investigate the clinical and pathological characteristics, treatment strategies, and prognosis of cervical clear cell carcinoma (CCCC) in patients not exposed to diethylstilbestrol in utero.
    UNASSIGNED: The patients diagnosed with CCCC at West China Second University Hospital of Sichuan University between January 2011 and Jun 2023 were enrolled for this retrospective study. The clinical characteristics and information on treatment and follow-up were collected. The Kaplan-Meier method and Cox regression analysis were performed to identify the relative variables for predicting progression-free survival (PFS) and overall survival (OS).
    UNASSIGNED: Of the 49 patients included, the Federation International of Gynecology and Obstetrics (FIGO) (2018) stage distribution was 37 (75.5%) stage I, 6 (12.2%) stage II, and 6 (12.2%) stage III. The median follow-up interval was 24.1 months. Six (12.2%) patients had a recurrence, and five (10.2%) patients died. The 5-year PFS rate was 86.8%, and the 5-year OS rate was 88.2%. No recurrence or death was detected in two patients who successfully completed fertility-preserving treatment and seven patients who underwent surgery to preserve ovaries. Two patients became pregnant, giving birth to two babies. The univariate analysis showed that FIGO stage, Pelvic lymph node (PLN) metastasis, lymph vascular space invasion, and depth of stromal invasion (P < 0.05) were significantly associated with PFS and OS. However, no significant prognostic factors were identified in the multivariate analysis.
    UNASSIGNED: Ovary-preserving treatment and fertility-preserving surgery are safe and feasible in early-stage CCCC. Surveillance other than adjuvant treatment may be a better choice for early-stage CCCC without any pathological risk factors. More targeted therapies and immunotherapy should be pursued in future studies.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    背景:成釉细胞纤维肉瘤(AFS)是一种罕见的恶性牙源性肿瘤,常见于年轻人,通常影响下颌区域。我们报告了一名来自上颌骨的老年女性患者中异常罕见且高度不典型的AFS病例。
    方法:一名66岁女性入院,有2周的左上磨牙肿块病史。CT扫描提示上颌骨有囊肿。切开活检显示梭形细胞肿瘤。MRI显示左侧上颌骨异常,表明可能的肿瘤病变。病人接受了上颌骨次全切除术,广泛的肿瘤切除,口内上皮瓣移植,和拔牙。组织学鉴定了具有可见有丝分裂图的非典型肿瘤细胞。免疫组化显示PCK和CD34表达阴性,但波形蛋白和SMA表达呈阳性。Ki-67增殖指数为30~50%。这些发现提示左上颌骨有一个潜在的恶性软组织肿瘤,倾向于AFS的诊断。患者接受术后放疗。随访6个月无复发。
    结论:基于重复的病理证据,我们报告了一例罕见的老年女性AFS源自上颌骨的病例。手术和术后放疗结果良好。
    BACKGROUND: Ameloblastic fibrosarcoma (AFS) is a rare malignant odontogenic tumor, commonly occurring in young adults and typically affecting the mandibular region. We report an exceptionally rare and highly atypical case of AFS in an elderly female patient originating from the maxillary bone.
    METHODS: A 66-year-old woman was admitted with a two-week history of a lump in her left upper molar. CT scans suggested a cyst in the maxillary bone. An incisional biopsy revealed a spindle cell neoplasm. MRI showed abnormalities in the left maxilla, indicating a possible tumorous lesion. The patient underwent a subtotal maxillectomy, wide tumor excision, intraoral epithelial flap transplantation, and dental extraction. Histology identified atypical tumor cells with visible mitotic figures. Immunohistochemistry showed negative for PCK and CD34 expression, but positive for Vimentin and SMA expression. The Ki-67 proliferation index ranged from 30 to 50%. These findings suggested a potentially malignant soft tissue tumor in the left maxilla, leaning towards a diagnosis of AFS. The patient received postoperative radiotherapy. There was no recurrence during the six-month follow-up.
    CONCLUSIONS: Based on repeated pathological evidence, we report a rare case of an elderly female with AFS originating from the maxillary bone. Surgery and postoperative radiotherapy resulted in a favorable outcome.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    接受辅助放疗的左侧乳腺癌女性因缺血性心脏病导致的心脏死亡率增加;迄今为止,尚未确定晚期心脏/肺部发病率或死亡率的阈值剂量。我们调查了接受全面淋巴结照射的左侧乳腺癌女性发生心脏死亡和放射性肺炎的可能性。还解决了自由呼吸(FB)和深吸气屏气(DIBH)技术之间的剂量学参数差异。根据NTCP计算,与FB技术相比,DIBH的心源性死亡概率显著降低(p<0.001).放射性肺炎的风险没有临床意义。FB和DIBH计划之间的覆盖率没有差异。对于V20,V30和同侧总肺容积,DIBH计划中健康结构的剂量明显低于FB计划。吸气门控减少了心脏吸收的剂量而不影响目标范围,从而降低了心脏死亡的可能性。
    Women with left-sided breast cancer receiving adjuvant radiotherapy have increased incidence of cardiac mortality due to ischemic heart disease; to date, no threshold dose for late cardiac/pulmonary morbidity or mortality has been established. We investigated the likelihood of cardiac death and radiation pneumonitis in women with left-sided breast cancer who received comprehensive lymph node irradiation. The differences in dosimetric parameters between free-breathing (FB) and deep inspiration breath hold (DIBH) techniques were also addressed. Based on NTCP calculations, the probability of cardiac death was significantly reduced with the DIBH compared to the FB technique (p < 0.001). The risk of radiation pneumonitis was not clinically significant. There was no difference in coverage between FB and DIBH plans. Doses to healthy structures were significantly lower in DIBH plan than in FB plan for V20, V30, and ipsilateral total lung volume. Inspiratory gating reduces the dose absorbed by the heart without compromising the target range, thus reducing the likelihood of cardiac death.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    背景:瘢痕疙瘩是瘢痕组织的异常增生,其生长超出损伤的原始边缘。即使在完全切除后,复发是常见的,在皮肤病学中构成了一个鲜为人知的挑战.缺乏大型前瞻性临床试验,因此,治疗建议基于回顾性分析和小型队列研究.建议复发性瘢痕疙瘩进行表面放疗;然而,成功率差异很大。本研究的目的是评估切除术后软X射线放疗后瘢痕疙瘩的复发率及其相关因素。
    方法:我们回顾了所有患者的回顾性资料,在三级转诊中心进行了6个疗程的辅助切除后软X线放射治疗,其中包括12个灰色,皮肤科,苏黎世大学医院,瑞士,2005年至2018年。我们将个体瘢痕疙瘩作为单独的病例进行了分析。成功的治疗被定义为在2年内没有复发的迹象。
    结果:在确定的200名患者中,90例符合纳入标准,纳入最终分析。在90名患者中,对104例瘢痕疙瘩进行分析。瘢痕疙瘩主要位于躯干(49%),主要由先前的手术引起(52.2%)。50%的瘢痕疙瘩在治疗后2年内没有复发。导致复发的一个重要因素是先前治疗的存在,与先前的局部治疗,如类固醇注射或5FU,导致大多数复发。69.2%复发的瘢痕疙瘩病例经过预处理。软X线放疗耐受性良好,34%的患者注意到治疗后色素沉着过度,特别是非白种人患者(61.3%)。
    结论:治疗难治性瘢痕疙瘩困难。切除后放疗是一种既定的辅助治疗选择,然而,复发率很高,尤其是预处理过的瘢痕疙瘩.需要进行前瞻性研究,以确定切除后放疗的确切剂量和分数,以确定最佳放射参数。
    BACKGROUND: Keloid is an abnormal proliferation of scar tissue that grows beyond the original margins of the injury. Even after complete resection, recurrences are common and pose a poorly understood challenge in dermatology. There is lack of large prospective clinical trials; thus, treatment recommendations are based on retrospective analyses and small cohort studies. Superficial radiotherapy is recommended in recurrent keloids; however, the successful treatment rates vary greatly. The aim of this study was to evaluate the keloid recurrence rate after post-excision soft X-ray radiotherapy and the associated factors.
    METHODS: We reviewed retrospective data of all patients, treated with adjuvant post-excision soft X-ray radiotherapy with 12 Gy in 6 sessions at the tertiary referral center, Department of Dermatology, University Hospital Zurich, Switzerland, between 2005 and 2018. We analyzed individual keloids as separate cases. Successful treatment was defined as no sign of recurrence within 2 years.
    RESULTS: Of the 200 identified patients, 90 met the inclusion criteria and were included in the final analysis. In 90 patients, 104 cases of treated keloids were analyzed. Keloids were mainly located on the trunk (49%) and were mostly caused by previous surgery (52.2%). 50% of the keloids did not relapse within 2 years after therapy. A significant factor leading to recurrence was the presence of previous therapy, with prior topical therapies, such as steroid injections or 5-fluorouracil, leading to most relapses. 69.2% of keloid cases who relapsed were pretreated. Soft X-ray radiotherapy was well tolerated, with posttreatment hyperpigmentation noted in 34% of patients, particularly in patients with non-Caucasian origin (61.3%).
    CONCLUSIONS: Treatment of refractory keloids is difficult. Post-excision radiotherapy is an established adjuvant treatment option; nevertheless, recurrence rates are high, especially in pretreated keloids. Prospective studies determining the exact dosage and fraction of post-excisional radiotherapy are needed to determine the optimal radiation parameters.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Case Reports
    内淋巴囊肿瘤(ELST)是一种罕见的病变。它可能是偶发的或与VonHippel-Lindau综合征有关。进行性听觉前庭症状是典型临床表现的特征。这里,我们报告了一个因肿瘤压迫导致的急性颅内高压(IH)的ELST的独特病例,紧急枕下去骨瓣减压术(SDC)成功治疗。
    一名33岁女性曾接受过活检和脑室-腹腔分流术。组织病理学发现了一个ELST。一年后,她出现了头痛,呕吐,和脑干受压引起的嗜睡。执行了紧急SDC。一个月后,术前进行血管内栓塞和部分肿瘤切除。6个月后给予辅助放疗(RT)治疗。自从上次手术以来,她已经接受了8年的随访,肿瘤保持稳定.
    ELST通常具有进行性临床病程。这是由于肿瘤压迫导致的急性IH的独特病例。肿瘤的高血管化和血管内栓塞的不可用性阻止了其切除。SDC是一种替代方法。最后的治疗包括肿瘤栓塞,手术切除,和RT。在最后一次手术后的8年内没有观察到进展,长期随访是必要的。
    UNASSIGNED: Endolymphatic sac tumor (ELST) is a rare lesion. It may be sporadically or associated with Von Hippel-Lindau syndrome. Progressive audiovestibular symptoms characterize the typical clinical presentation. Here, we report a unique case of ELST with acute intracranial hypertension (IH) due to tumor compression, successfully treated with an urgent suboccipital decompressive craniectomy (SDC).
    UNASSIGNED: A 33-year-old woman previously underwent a biopsy and ventriculoperitoneal shunt. The histopathological finding revealed an ELST. One year later, she developed headache, vomiting, and somnolence due to brainstem compression. An urgent SDC was performed. One month later, preoperative endovascular embolization and partial tumor resection were carried out. After 6 months adjuvant radiotherapy (RT) therapy was administered. She has been under follow-up for 8 years since the last surgical procedure, and the tumor remains stable.
    UNASSIGNED: ELST generally has a progressive clinical course. This is a unique case with acute IH due to tumor compression. The tumor\'s high vascularity and the unavailability of endovascular embolization precluded its resection. SDC was an alternative approach. The final treatment included tumor embolization, surgical resection, and RT. No progression was observed for 8 years after the last procedure, and long-term follow-up is warranted.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    胰腺癌是一种侵袭性恶性肿瘤。尽管高质量的手术需要辅助治疗,但复发率非常高。辅助治疗的发展经历了几十年,并逐渐从单药化疗发展到多药化疗。在胰腺癌中有活性的两种重要药物是5-氟尿嘧啶和吉西他滨,几个组合在随后的试验中显示出更好的结果,最新的PRODIGE24试验显示中位生存期为54.4个月.新辅助治疗在可切除癌症中的作用仍在发展。由于历史试验的有争议的结果,辅助放疗的作用尚不明确。
    Pancreatic cancer is an aggressive malignancy. Recurrences are very high despite high-quality surgery necessitating adjuvant therapy. The evolution of adjuvant therapy took several decades and gradually evolved from single-agent chemotherapy to multi-agent chemotherapy. The two important agents that are active in pancreatic cancer are 5-fluorouracil and gemcitabine, and with several combinations showing better results in the subsequent trials, the most recent trial PRODIGE 24 shows a median survival of 54.4 months. The role of neoadjuvant therapy is still evolving in resectable cancers. The role of adjuvant radiotherapy is not well defined due to controversial results from historical trials.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    尽管手术切除被广泛认为是治疗肝癌的最有效方法,其对位于中央的肝细胞癌(HCC)的安全性和有效性仍不令人满意。因此,寻求综合治疗,比如联合辅助放疗,提高患者的预后至关重要。通过招募2015年6月至2020年接受中央位置HCC手术切除的患者,他们被分为肝切除联合辅助放疗(LR+RT)和单纯肝切除(LR)组。使用倾向评分的计算和Cox比例风险回归模型。193名患者被招募到聚集中,包含88个正在接受LR+RT的,而105用LR处理。RT被证实是复发的独立预后因素(HR0.60)。在倾向得分分析中,辅助放疗与更好的无病生存期(DFS)之间存在显著关联(匹配,HR0.60;倾向评分调整,HR0.60;逆概率加权,HR0.63)。两组间DFS差异明显(p值=0.022),在亚组分析中,RT显着下调了早期复发(p值<0.05)。E值的计算揭示了不可测量的混杂的鲁棒性。肝脏手术切除与RT的组合是安全和有效的对患者的中央定位肝癌,这将显著提高预后和减少肝癌的早期复发。
    Despite that surgical resection is widely regarded as the most effective approach to the treatment of liver cancer, its safety and efficacy upon centrally located hepatocellular carcinoma (HCC) remain unsatisfactory. In consequence, seeking an integrated treatment, like combined with adjuvant radiotherapy, to enhance the prognosis of patients is of critical importance. By recruiting patients undergoing surgical resection for centrally located HCC ranging from June 2015 to 2020, they were divided into liver resection combined with adjuvant radiotherapy (LR + RT) and mere liver resection (LR) groups. The calculation of propensity score and model of Cox proportional hazards regression were utilized. 193 patients were recruited in aggregation, containing 88 ones undergoing LR + RT, while 105 handled with LR. RT was verified to be an independent factor of prognosis for relapse (HR 0.60). In propensity-score analyses, significant association existed between adjuvant radiotherapy and better disease-free survival (DFS) (Matched, HR 0.60; Adjustment of propensity score, HR 0.60; Inverse probability weighting, HR 0.63). The difference of DFS was apparent within two groups (p value = 0.022), and RT significantly down-regulated early relapse (p value < 0.05) in subgroup analysis. The calculation of E-value revealed robustness of unmeasured confounding. The combination of liver surgical resection with RT is safe and effective towards patients with centrally located HCC, which would notably enhance the prognosis and decrease the early relapse of HCC.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    背景:新诊断的p16阳性口咽鳞状细胞癌(p16+OPSCC)的降阶梯策略,目的是在不影响疾病控制的情况下降低与治疗相关的发病率。一种策略是经口机器人手术前的新辅助顺铂和多西他赛化疗(NAC+S),以病理学为基础的风险适应辅助治疗。
    方法:我们检查了接受NAC+S的患者的无复发生存期(RFS)。
    结果:比较2008年至2023年103例患者的结果,92%的患者避免了辅助治疗,并且与辅助治疗的患者相比,2年无复发生存率(RFS)明显更高(95.9%vs.43.8%,p=0.0049)结论:我们的发现表明,在NAC+S之后,基于病理学的风险适应的辅助治疗的省略似乎不会增加复发风险,并且NAC可以识别具有良好肿瘤生物学特性的患者。在没有辅助治疗的情况下,2年RFS概率超过95%。Further,该研究确定了一个尽管接受了三联疗法治疗但仍有疾病复发的患者亚组.尽管有局限性,包括回顾性设计和适度的样本量,受控NAC+S研究的数据倡导者。
    BACKGROUND: De-escalation strategies for newly-diagnosed p16-positive oropharyngeal squamous cell carcinoma (p16+ OPSCC), aim to reduce treatment-related morbidity without compromising disease control. One strategy is neoadjuvant cisplatin and docetaxel chemotherapy (NAC + S) before transoral robotic surgery, with pathology-based risk-adapted adjuvant treatment.
    METHODS: We examined the recurrence-free survival (RFS) for patients who received NAC + S.
    RESULTS: Comparing outcomes in 103 patients between 2008 and 2023, 92% avoided adjuvant treatment and showed significantly higher 2-year recurrence-free survival (RFS) compared to those with adjuvant treatment (95.9% vs. 43.8%, p = 0.0049) CONCLUSION: Our findings suggest that pathology-based risk-adapted omission of adjuvant treatment following NAC + S does not appear to elevate recurrence risk and that NAC may identify patients with favorable tumor biology, yielding a 2-year RFS probability exceeding 95% without adjuvant treatment. Further, the study identifies a patient subset experiencing disease recurrence despite triple modality therapy. Despite limitations, including a retrospective design and modest sample size, the data advocate for controlled NAC + S studies.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    背景:辅助放疗是早期乳腺癌患者治愈性治疗的关键组成部分。近年来,在我们的组织中,该人群首选两种加速部分乳房照射(APBI)技术:基于电子的术中放射治疗(IORT)和基于直线加速器的外部束放射治疗,特别是调强放射治疗(IMRT)。与IMRT相比,最近发布的评估这些技术的长期随访数据激发了对IORT的健康技术重新评估。
    方法:我们开发了一个马尔可夫模型来模拟早期乳腺癌女性的健康状态转变,在使用IORT或IMRT技术进行肿块切除术和辅助APBI后。从投资角度评估了私人医疗服务提供者的成本效益,使用寿命年(LYs)和无复发寿命年(RFLYs)作为获益的衡量标准,以及各自的质量调整。预期成本和收益,并报告了增量成本效益比(ICER)。最后,在IORT患者中使用较低的IORT局部复发和转移率进行敏感性和情景分析以评估成本效益。如果设备维护费用被取消。
    结果:在所有情况下,IORT技术均由IMRT主导(即,更少的好处和更大的成本)。尽管在福利方面发现了微小的差异,尤其是对于Lys来说,IORT的成本要高得多。对于IORT复发率和转移率较低的敏感性分析,和没有设备维护成本的情景分析,IORT仍然以IMRT为主。
    结论:对于这一组患者,IMRT是,至少,在预期收益方面不劣于IORT,成本大大降低。因此,应考虑IORT撤资,支持在这些患者中使用IMRT。
    BACKGROUND: Adjuvant radiotherapy represents a key component in curative-intent treatment for early-stage breast cancer patients. In recent years, two accelerated partial breast irradiation (APBI) techniques are preferred for this population in our organization: electron-based Intraoperative radiation therapy (IORT) and Linac-based External Beam Radiotherapy, particularly Intensity-modulated radiation therapy (IMRT). Recently published long-term follow-up data evaluating these technologies have motivated a health technology reassessment of IORT compared to IMRT.
    METHODS: We developed a Markov model to simulate health-state transitions from a cohort of women with early-stage breast cancer, after lumpectomy and adjuvant APBI using either IORT or IMRT techniques. The cost-effectiveness from a private health provider perspective was assessed from a disinvestment point of view, using life-years (LYs) and recurrence-free life-years (RFLYs) as measure of benefits, along with their respective quality adjustments. Expected costs and benefits, and the incremental cost-effectiveness ratio (ICER) were reported. Finally, a sensitivity and scenario analyses were performed to evaluate the cost-effectiveness using lower IORT local recurrence and metastasis rates in IORT patients, and if equipment maintenance costs are removed.
    RESULTS: IORT technology was dominated by IMRT in all cases (i.e., fewer benefits with greater costs). Despite small differences were found regarding benefits, especially for LYs, costs were considerably higher for IORT. For sensitivity analyses with lower recurrence and metastasis rates for IORT, and scenario analyses without equipment maintenance costs, IORT was still dominated by IMRT.
    CONCLUSIONS: For this cohort of patients, IMRT was, at least, non-inferior to IORT in terms of expected benefits, with considerably lower costs. As a result, IORT disinvestment should be considered, favoring the use of IMRT in these patients.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

公众号